Special protocol assessment for HGS/GSK LymphoStat-B
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA grants an SPA for Phase III trials of LymphoStat-B (belimumab) in active systemic lupus erythematosus, Human Genome Sciences announces Oct. 26. The pivotal program, expected to start by year-end, will include two superiority trials, the 52-week BLISS-52 and 76-week BLISS-76 studies, each to enroll 810 patients with serologically active SLE. The SPA accepts a combined patient response rate endpoint that "emerged directly" from GSK and HGS' analysis of a Phase II study that failed to show clinical benefit at week 24 (1Pharmaceutical Approvals Monthly August 2006, p. 32)...
You may also be interested in...
Genentech Rituxan Failed Lupus Trial Also Takes Down Ocrelizumab For SLE
Genentech is abandoning development of both its anti-CD20 monoclonal antibodies for systemic lupus erythematosus after the failure of Rituxan (rituximab) in the Phase II/III EXPLORER trial cast doubt on the validity of targeting the CD20 antigen on B-cells as an approach to SLE.
HGS LymphoStat-B to begin Phase III in Q4
Human Genome Sciences will begin a Phase III trial of LymphoStat-B (belimumab) in patients with active systemic lupus erythematosus in the fourth quarter of 2006, the company announces Aug. 9. HGS expects a $24 mil. milestone payment from development partner GlaxoSmithKline in the third quarter. HGS collaborated with GSK to design the Phase III study, which has an endpoint that combines response rate and elements of the SELENA SLEDAI and BILAG disease activity indices, as well as the Physician's Global Assessment index. A Phase II study failed to show a clinical benefit at week 24, but HGS previously indicated its belief that the Phase II data are strong enough to move into Phase III studies (1Pharmaceutical Approvals Monthly July 2006, p. 16)...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.